Senate Generic Rx Bill Too “One-Sided” For House, GSK Assures Investors
Executive Summary
Any Waxman/Hatch Act reform legislation that emerges from the House would be more balanced than the bill currently moving through the Senate, GlaxoSmithKline Chief Operating Officer Robert Ingram maintained during a July 24 conference call